H ypertrophic cardiomyopathy (HCM) is an inherited myocardial disorder characterized by increased left ventricular wall thickness, which is not solely explained by abnormal loading conditions. 1 The clinical perception is that the more severe the hypertrophy, the higher is the risk of sudden cardiac death (SCD) 2 and left ventricular maximal wall thickness (MWT) is one of several clinical features used to guide prophylactic implantable cardioverter defibrillator (ICD) therapy. 1-3 However, patients at the most severe end of the hypertrophy spectrum are under-represented in clinical studies 4,5 and their assumed highrisk status is based on extrapolation of data from other patient subgroups. A recent multicenter study reported that patients with left MWT ≥35 mm were not at higher risk of SCD compared with patients with lesser hypertrophy, 6 echoing the findings of an earlier cohort study. 7 The aim of this study was to examine the relation between MWT and the risk of SCD.
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illustrated using the HCM Risk-SCD model, 8 and survival analysis was used to examine how the observed SCD end points compared with the risk estimates. The phenotype, genotype, and outcomes of patients with extreme MWT (≥35 mm) are described to corroborate the risk estimates and survival analysis.
The study conforms to the principles of the Helsinki declaration. The sponsors of this study did not have a role in study design, data collection, analysis, and interpretation. C.O'M., F.J., R.Z.O., and P.M.E. had access to all data and final responsibility to submit the article. The authors from each participating center guarantee the integrity of data from their institution. All investigators have agreed to the article as written. Author contributions can be found in the Data Supplement. Patients at A Coruña University Hospital (Spain), Unit of Inherited Cardiovascular Diseases at the 1st Department of Cardiology (Athens), University Hospital Virgen de la Arrixaca (Spain), and Monaldi Hospital (Italy) provided written informed consent. The ethics committees at Heart Hospital (United Kingdom), and Institute of Cardiology at the University of Bologna (Italy) were informed, but approval was not required under local research governance arrangements.
Study Population and Participating Centers
The study cohort consisted of consecutively evaluated patients with HCM from 6 European centers. HCM was defined as a maximum left ventricular wall thickness ≥15 mm unexplained by abnormal loading conditions 1 or in accordance with published criteria for the diagnosis in relatives of patients with unequivocal disease. 9 All patients were ≥16 years of age, with no history of ventricular fibrillation or sustained ventricular tachycardia. A risk prediction model for SCD (HCM Risk-SCD) was previously derived from this retrospective, multicenter longitudinal cohort study of 3675 patients using the Cox proportional hazards model and internally validated using bootstrapping. Univariable Cox regression models were fitted for each continuous predictor to test the assumption of linearity with the outcome. To develop the final risk model, multivariable Cox regression models were fitted with all predictors and quadratic terms for the continuous predictors where nonlinearity was found. Of 8 prespecified predictors, age, MWT, left atrial diameter, left ventricular outflow tract gradient, family history of SCD, nonsustained ventricular tachycardia, and unexplained syncope were associated with SCD/appropriate ICD shocks at the 15% significance level. MWT was observed to have a nonlinear association with SCD; hence, a quadratic term was included for this predictor. These predictors were included in the final model used to estimate individual probabilities of SCD at 5 years. Procedures for collecting clinical data, the detailed clinical characteristics of this cohort, and the methods used to develop the risk model have been reported previously. 8 Since the publication of HCM Risk-SCD, 2 patients (including 1 affected by an SCD end point) were found to have a metabolic disorder and were excluded from the current study.
Study Outcomes
The primary study end point was SCD defined as a composite of witnessed sudden death with or without documented ventricular fibrillation, death within 1 hour of new symptoms, nocturnal deaths with no antecedent history of worsening symptoms, aborted SCD, or an appropriate ICD shock. 10 Secondary study end points for exploratory analyses were as follows:
1. Cardiovascular death defined as a composite of SCD, death from heart failure (death preceded by signs or symptoms of heart failure, including cardiogenic shock), stroke, pulmonary or peripheral arterial embolization, death from a cardiac procedure or myocardial infarction, or orthotopic heart transplantation for end-stage heart failure, as previously described. 10 2. All-cause mortality defined as a composite of cardiovascular death (as defined above) and any other cause of death.
General Statistical Methods
All statistical analyses were performed using STATA (versions 11 and 13). Variables are expressed as mean±SD, median (25th percentile to 75th percentile) or counts and percentages as appropriate. Least squares linear regression was used to assess the relation of MWT groups to continuous variables. Chi-squared tests were used to assess the relation of MWT to categorical variables. 11 The Bonferroni correction was applied as a multiple testing correction strategy.
MWT as a Continuous Variable and the Estimated Probability of SCD at 5 Years
The relation between MWT as a continuous variable (mm) and 5-year SCD risk was examined graphically. The risk was calculated using the HCM Risk-SCD model 8 for all MWT values observed in the study (ranging from minimum to maximum), with continuous variables set to their mean value for the study cohort and dichotomous variables set to 0 (absence) and 1 (presence) to show the effect on risk estimates.
Statistical Models Examining the Relation of MWT in 5-mm Subgroups to Clinical Outcomes
In accordance to previous studies, outcomes were examined in 5 mm MWT subgroups. [4] [5] [6] The Cox proportional hazards model was used to examine SCD using the HCM Risk-SCD predictor variables. 8 The same variables were used in 2 additional Cox proportional hazards models to explore the relation of MWT to the secondary study outcomes (cardiovascular death and all-cause mortality). The followup time for each patient was calculated from the date of their first evaluation to the date of reaching the primary or secondary end point, or to the date of their most recent evaluation. The annual event rate was calculated by dividing the number of patients reaching the end point by the total follow-up period for that end point. The cumulative probability for the occurrence of an outcome was estimated using the
WHAT IS KNOWN
• Hypertrophic cardiomyopathy is an inherited cardiac disorder associated with sudden cardiac death (SCD).
• Some studies have shown a trend toward a higher risk of sudden death or implantable cardioverter defibrillator discharge with increasing left ventricular maximal wall thickness.
• International guidelines advocate implantable cardioverter defibrillator implantation in patients with severe hypertrophy.
WHAT THE STUDY ADDS
• The risk of SCD in patients with hypertrophic cardiomyopathy does not vary in direct proportion to the severity of hypertrophy. Instead, SCD has a complex, inverted U-shaped relation with maximal wall thickness.
• Contrary to previous studies, we found that patients with extreme hypertrophy may have relatively good survival from SCD in the absence of other high risk clinical features.
• Implantable cardioverter defibrillator implantation should not be guided solely on the severity of left ventricular hypertrophy; a more global SCD risk assessment, which integrates other risk factors should be used. Maximal Wall Thickness and Sudden Death in HCM Kaplan-Meier method. Data were assumed to be missing at random and values for the missing predictors were imputed using multiple imputation techniques based on chained equations as previously described. 8
Genetic Data
The cohort was not systematically tested for mutations of sarcomere myofilament genes. The results of ad hoc genetic testing of patients with extreme hypertrophy are presented. In the absence of evidence to the contrary (eg, lack of cosegregation with disease in a family), variants previously reported in the literature as mutations were considered disease causing. The pathogenicity of unreported sequence variants was determined by in silico prediction methods and where cosegregation analysis was possible.
Results

Baseline Clinical Characteristics
The study population consisted of 3673 patients with mean MWT 19.6±5 mm (minimum, 7 mm [diagnosis of HCM on the basis of familial criteria]; maximum, 43 mm; Figure 1 ). Thirteen patients (0.35%) had missing MWT data at baseline (patterns of missing data have been reported elsewhere 8 ). The baseline clinical characteristics are shown in Table 1 . The associations of baseline clinical characteristics to MWT are illustrated in Figure 2 (continuous variables) and Figure 3 (categorical variables).
Follow-Up Characteristics and Clinical Outcomes in the Entire Cohort
The 3673 patients were followed up for a total of 24 298 patient-years (median, 5.7 [2.8-9.2] years). The annual rate of SCD end points was 0.8% (95% confidence interval [CI], 0.7-0.9) with a 5-year cumulative incidence of 3.7% (95% CI, 3.1-4.5). The annual rate of cardiovascular death was 1.7% (95% CI, 1.5-1.9) with a 5-year cumulative incidence of 7.0% (95% CI, 6. 
MWT as a Continuous Variable and the Estimated Probability of SCD at 5 Years
The estimated risk of SCD at 5 years had a nonlinear relation to MWT as shown in Figure 4 . The inverted U-shape of this relation means that the estimated risk of SCD increases with worsening hypertrophy to reach plateau and declines thereafter. The inverted U-shaped curve becomes more pronounced with increase in prognostic index, that is, with higher risk of SCD. This suggests that, for a specified change in MWT, there seems to be a variable change both in the magnitude and direction of SCD risk, depending on other risk predictors; eg, an increase in MWT from 20 to 25 mm is associated with a higher increase in the risk of SCD when other high-risk features are present (high prognostic index).
Relation of MWT in 5-mm Subgroups to SCD and Additional Exploratory Analyses
The Kaplan-Meier curves showing the cumulative incidence of the SCD end point, cardiovascular deaths, and all-cause mortality in 5-mm MWT groups are shown in Figure 5 . The effect of 5-mm increments in MWT on the primary study outcome (SCD) and the secondary exploratory outcomes (cardiovascular deaths and all-cause mortality) was examined in 3 multivariable Cox proportional hazards models shown in Table 2 . Compared with HCM patients with MWT≤14 mm, patients with MWT≥35 mm did not have a significantly higher risk for SCD, cardiovascular death, or all-cause mortality.
Follow-Up Characteristics and Clinical Outcomes in Patients With Extreme Hypertrophy
The 47 patients (1% of the cohort) with MWT≥35 mm had longer follow-up (median, 9. 1 from systemic embolization; Table 3 ). All observed cardiovascular deaths in patients with MWT≥35 mm occurred beyond 5 years of follow-up. The annual rate of the SCD end point was 0.2% (95% CI, 0.03-1.60) with a 10-year cumulative incidence of 3.0% (95% CI, 0.4-20.0). The annual rate of cardiovascular death was 0.9% (95% CI, 0.3-2.6) with a 10-year cumulative incidence of 10.0% (95% CI, 0.3-29.0). A single patient with MWT≥35 mm died from noncardiac causes (complications of viral respiratory tract infection after 4.8 years of follow-up). The annual all-cause mortality rate was 1.1% (95% CI, 0.5-2.7) with a 10-year cumulative incidence of 12.0% (95% CI, 0.5-31.0).
Sarcomeric Protein Gene Mutations in Patients With Extreme Hypertrophy
Genetic testing was performed in 37 (79%) patients with MWT≥35 mm. Sarcomeric protein gene mutations were detected in 16 patients (43%). Mutations in myosin-binding protein C (MYBPC3) or β-myosin heavy chain (MYH7) mutations were detected in 13 (81%) of the 16 mutationpositive patients and 1 patient (6%) was double heterozygote. The sarcomeric protein gene mutations and clinical characteristics of the 16 genotype-positive patients are shown in Table  II in the Data Supplement. Variants of unknown significance are also shown in the Data Supplement. Of the remaining 31 patients (21 mutation negative and 10 not genetically tested), 2 (6%) received a pacemaker during follow-up and none had evidence of preexcitation. The baseline clinical characteristics of mutation-positive and mutation-negative patients, and patients who were not genetically tested, are shown in Table  III in the Data Supplement.
Discussion
Until recently, it was assumed that the risk of SCD in patients with HCM increased in direct proportion to the severity of hypertrophy. 2, 4, 5 This study shows that the relationship between SCD risk and MWT is more complex than previously thought in that risk increases with worsening hypertrophy to reach plateau and declines thereafter. Contrary to received opinion, the incidence of SCD in patients with extreme hypertrophy may not be excessively high in the absence of other clinical risk factors. There is no clear explanation for the inverted U-shaped relation of MWT to SCD. All patients with HCM have the structural substrate for ventricular arrhythmias. Disarray †During the study period, a total of 558 (15%) patients were treated with an ICD. and cardiac hypertrophy support reentry, 12 and arrhythmias are often triggered by premature ventricular ectopics. 13 It is also likely that sustained ventricular arrhythmias are precipitated only when transient phenomena (eg, myocardial ischemia secondary to left ventricular outflow tract obstruction) reduce the threshold for arrhythmogenesis. 13, 14 Patients at the extremes of the MWT spectrum may have a high arrhythmia threshold or be less exposed to transient functional modulators. We cannot exclude the coexistence of other unknown protective factors that operate at the extremes of the MWT spectrum and confer a survival advantage. Advanced tissue characterization techniques using CMR or PET may further improve our understanding of the arrhythmogenic substrate in HCM. 15 
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In this study, patients with extreme hypertrophy experienced few clinical events, despite longer follow-up. These data are in keeping with the limited literature on hypertrophy of this severity. In a study of 30 patients with MWT≥35 mm, there was only 1 SCD end point after a mean follow-up of 6 years (approximate event rate, 0.6% per year; 95% CI, 0.08-3.9). 7 In a more recent multivariable analysis, which examined the temporal association of unexplained syncope to SCD, 30 patients with MWT≥35 mm were found to have a similar risk of SCD to patients with MWT≤10 mm (hazard ratio, 0.66; 95% CI, 0.21-17.87). 6 In all published studies, the CIs associated with the risk estimates are wide because of small patient numbers, which is an inherent limitation when studying the extremes of the phenotypic spectrum.
Since 2003, international guidelines have considered MWT≥30 mm as a risk factor for SCD, 2,3 but the data to support this recommendation are conflicting ( Figure 6 ). [4] [5] [6] 10, [16] [17] [18] [19] [20] [21] [22] [23] [24] In this context, our findings suggest that ICD implantation should not be based solely on the severity of left ventricular hypertrophy and that a more global SCD risk assessment, integrating other risk factors, should be used.
In this study, the typical patient with MWT≥35 mm was a young man and the prevalence of left ventricular outflow tract obstruction ≥50 mm Hg, nonsustained ventricular tachycardia, left atrial dilation, NYHA class III/IV and unexplained syncope was less than other MWT subgroups. The comparatively small left atrial size and good functional capacity in this subgroup may be related to the lower prevalence of significant left ventricular outflow tract obstruction. 17, 21, 22 Although most patients were <40 years of age, MWT ≥35 mm was not exclusively seen in young patients. The male preponderance is not unique to this patient subgroup and may relate to sex hormone receptor gene variations, social factors, or diagnostic bias. 25, 26 We hypothesized that the genetic substrate in patients with MWT ≥35 mm might differ from patients with lesser degrees of hypertrophy. However, the overall prevalence of sarcomeric protein gene mutations in patients with MWT ≥35 mm was comparable to that reported in a recent pooled analysis of unselected cohorts of unrelated HCM patients and was similarly dominated by MYH7 and MYBPC3 mutations. 27 In addition, none of the observed mutations have been consistently linked with MWT ≥35 mm. Complex genotypes have been associated with severe hypertrophy, [28] [29] [30] but this study shows that the reverse is not true because the majority of cases of MWT ≥35 mm were not linked to a complex genotype. HCM with extreme MWT can be a feature of some glycogen storage diseases and it is conceivable that some patients had undiagnosed metabolic disorders. The risk of SCD at 5 years was calculated using HCM Risk-SCD with the following predictors kept constant to the cohort mean: age, 48 years; maximal left ventricular outflow tract gradient, 12 mm Hg; left atrial diameter, 44 mm. The 4 curves represent the estimated risk with all possible combinations of nonsustained ventricular tachycardia (NSVT) and unexplained syncope, keeping family history of SCD=0. In all cases, the risk of SCD increases up to a point, and once a plateau is reached, the risk declines. The vertical reference lines represent the 1% and 99% centiles of maximal wall thickness in this cohort. Variations in family history of SCD also showed the same pattern (plots not shown for clarity).
Figure 5.
Kaplan-Meier curves showing the incidence of sudden cardiac death (SCD) end points, cardiovascular death, and all-cause mortality. Patients were classified in six 5-mm groups on the basis of maximum wall thickness, in accordance to previous studies. [4] [5] [6] A, Cumulative incidence for the SCD end point. B, Cumulative incidence for cardiovascular death. C, Cumulative incidence for all-cause mortality. Maximal Wall Thickness and Sudden Death in HCM However, the lack of electrocardiographic evidence of preexcitation, the low prevalence of permanent pacemaker implantation, and the relatively benign natural history make diseases such as Danon-and PRKAG2-related cardiomyopathy, 31 unlikely causes for the phenotype in mutationnegative patients. It is more likely that other genomic and environmental modifiers are responsible for the severe phenotypic expression.
Limitations
Although this is the largest cohort of HCM patients with MWT ≥35 mm, the number of patients is still small, reflecting the low prevalence of this phenotype. The findings of this study are limited to patients without a history of aborted SCD and exclusion of patients with MWT ≥35 mm, and a previous history of aborted SCD could give the impression of better prognosis. However, patients with MWT ≥35 mm are also scarce in previously published cohorts with aborted SCD 32, 33 ; this is an unlikely explanation for the observations of this study. The findings of this study should not be extrapolated to pediatric (<16 years) patients because they were excluded from the study. Furthermore, HCM Risk-SCD estimates use MWT as the sole measure of left ventricular hypertrophy, and the effect of the septal morphology 34 or extent of hypertrophy 5 on SCD risk was not examined.
Conclusions
The risk of SCD has a complex, nonlinear relation to MWT in patients with HCM. Patients with MWT≥35 mm may have a relatively good prognosis for SCD despite the extreme severity of hypertrophy. The pathophysiological mechanisms behind this observation require further study, but ICD implantation should not be guided solely on the severity of left ventricular hypertrophy. The number of end points per 5-mm subgroup is shown in Table I in the Data Supplement. CI indicates confidence interval; FHSCD, family history of sudden cardiac death; LA, left atrium; LVOTG, left ventricular outflow tract gradient at rest or Valsalva; and NSVT, nonsustained ventricular tachycardia. All patients were in New York Heart Association I/II and in sinus rhythm at baseline evaluation. CVS indicates cardiovascular death; FHSCD, family history of sudden cardiac death; LA, left atrium; LVedd, left ventricular end diastolic dimension; LVOTg, left ventricular outflow tract gradient at rest or Valsalva; MWT, maximal wall thickness; NSVT, nonsustained ventricular tachycardia; and SCD, sudden cardiac death. Figure 6 . Risk of sudden cardiac death (SCD) and maximal wall thickness ≥30 mm in previous survival analyses. In all studies, the number of patients with maximal wall thickness ≥30 mm is small, and there is no consistent independent association with SCD. [4] [5] [6] 10, [16] [17] [18] [19] [20] [21] [22] [23] [24] The vertical reference line represents a hazard ratio of 1.
